GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (OTCPK:SHPHF) » Definitions » Other Current Liabilities

SHPHF (Sihuan Pharmaceutical Holdings Group) Other Current Liabilities : $343.7 Mil (As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group Other Current Liabilities?

Sihuan Pharmaceutical Holdings Group's other current liabilities for the quarter that ended in Jun. 2024 was $343.7 Mil.

Sihuan Pharmaceutical Holdings Group's quarterly other current liabilities increased from Jun. 2023 ($74.5 Mil) to Dec. 2023 ($335.3 Mil) and increased from Dec. 2023 ($335.3 Mil) to Jun. 2024 ($343.7 Mil).

Sihuan Pharmaceutical Holdings Group's annual other current liabilities declined from Dec. 2021 ($185.7 Mil) to Dec. 2022 ($100.9 Mil) but then increased from Dec. 2022 ($100.9 Mil) to Dec. 2023 ($335.3 Mil).

Sihuan Pharmaceutical Holdings Group Other Current Liabilities Historical Data

The historical data trend for Sihuan Pharmaceutical Holdings Group's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sihuan Pharmaceutical Holdings Group Other Current Liabilities Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sihuan Pharmaceutical Holdings Group Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Sihuan Pharmaceutical Holdings Group Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Sihuan Pharmaceutical Holdings Group's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sihuan Pharmaceutical Holdings Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (OTCPK:SHPHF) » Definitions » Other Current Liabilities
Comparable Companies
HKSE:02877 HKSE:03613 HKSE:01681 HKSE:01349 HKSE:01558 HKSE:02186 HKSE:06896 HKSE:02005 HKSE:02348 HKSE:02633 ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XSWX:SDZ XTAE:TEVA NSE:DIVISLAB VTRS
Traded in Other Exchanges
00460:Hong Kong
Address
Zhubang 2000, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025
Website
https://www.sihuanpharm.com
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segments; and the generic medicine segment which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.